Ionizable lipid metabolites are becoming increasingly important in clinical pharmacology as lipid nanoparticle (LNP)-based mRNA vaccines and therapeutics expand into chronic and repeat-dose applications. Following administration, ionizable lipids undergo biotransformation to generate metabolites that may differ from the parent compound in clearance, tissue distribution, persistence, and safety profile. Quantitative assessment and characterization of these metabolites are essential for understanding pharmacokinetics, biodegradability, accumulation potential, and safety liabilities such as liver accumulation, inflammatory responses, and repeat-dose tolerability. To support these evaluations, integrated LC–HRMS and LC–MS/MS bioanalytical quantitation strategies are employed to identify and monitor circulating hydrolysis metabolites in human plasma, addressing bioanalytical challenges associated with retaining highly polar metabolites, ion suppression, and matrix interference. Overall, a comprehensive ionizable lipid metabolite bioanalytical quantitation strategy is becoming a critical component of clinical pharmacology, translational ADME, and next-generation mRNA vaccine and therapeutic development.
Learning Objectives:
Understand the clinical pharmacology relevance of ionizable lipid metabolites in LNP-based mRNA vaccines and therapeutics, including their impact on biodegradability, systemic exposure, tissue persistence, and safety assessment.
Learn how hydrolysis metabolites of biodegradable ester-containing ionizable lipids are characterized and quantitatively monitored in human plasma following intravenous administration.
Gain insight into integrated LC–HRMS and LC–MS/MS quantitation strategies used to support metabolite profiling of Moderna’s proprietary ionizable lipid platform across clinical mRNA vaccine and therapeutic programs.
